X0002の新興薬剤に関する洞察と市場予測：2032年

X0002（イブプロフェナミン塩酸塩スプレー）は、新規経皮吸収型非ステロイド性抗炎症薬として、関節リウマチおよびOA治療薬として臨床開発中です。

Techfieldsは、新規薬剤-X0002の第III相臨床試験TF-X0002-31（Freedom-1）を膝関節OAの治療薬として米国内の56施設で開始しました。また、X0002噴霧装置に関する2回目のヒト要因試験を完了し、膝OA患者を対象とした2つの第II相臨床試験（うち1つは中国で実施）を終了しました。

前臨床試験では、OAのような疾患に対する必要投与量を98.5％以上削減できる可能性が示され、現在第III相臨床試験で検討中です。

当レポートでは、主要6ヶ国、カナダおよび韓国におけるX0002市場について調査し、市場の概要とともに、2024年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 変形性関節症に対するX0002の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 X0002市場評価

• 変形性関節症に対するX0002の市場展望
• 主要6ヶ国、カナダおよび韓国の分析
  • 主要6ヶ国、カナダおよび韓国における変形性関節症に対するX0002の市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国
  • カナダ
  • 韓国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: X0002, Clinical Trial Description, 2023
• Table 2: X0002, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: X0002 Market Size in the 6MM, Canada and Korea, in USD million (2019-2032)
• Table 6: X0002 Market Size in the US, in USD million (2019-2032)
• Table 7: X0002 Market Size in Germany, in USD million (2019-2032)
• Table 8: X0002 Market Size in France, in USD million (2019-2032)
• Table 9: X0002 Market Size in Italy, in USD million (2019-2032)
• Table 10: X0002 Market Size in Spain, in USD million (2019-2032)
• Table 11: X0002 Market Size in the UK, in USD million (2019-2032)
• Table 12: X0002 Market Size in Canada, in USD million (2019-2032)
• Table 13: X0002 Market Size in Korea, in USD million (2019-2032)

List of Figures

• Figure 1: X0002 Market Size in the 6MM, Canada and Korea, USD million (2019-2032)
• Figure 2: X0002 Market Size in the United States, USD million (2019-2032)
• Figure 3: X0002 Market Size in Germany, USD million (2019-2032)
• Figure 4: X0002 Market Size in France, USD million (2019-2032)
• Figure 5: X0002 Market Size in Italy, USD million (2019-2032)
• Figure 6: X0002 Market Size in Spain, USD million (2019-2032)
• Figure 7: X0002 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: X0002 Market Size in Canada, USD million (2019-2032)
• Figure 9: X0002 Market Size in Korea, USD million (2019-2032)

“"X0002 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about X0002 for osteoarthritis in the six major markets. A detailed picture of the X0002 for osteoarthritis in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada, and Korea for the study period 2019 -2032 is provided in this report along with a detailed description of the X0002 for osteoarthritis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the X0002 market forecast analysis for osteoarthritis in the 6MM, along with Canada and Korea, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in osteoarthritis.

Drug Summary:

X0002 (ibuprofenamine hydrochloride spray) is a novel transdermal NSAID under clinical development to treat rheumatoid arthritis and OA as a novel transdermal drug.

Techfields has initiated a Phase III clinical trial of a novel drug-X0002, TF-X0002-31 (Freedom-1), in 56 sites in the US for the treatment of knee OA. They have completed the second human factors study for X0002 spray devices, and two Phase II trials in patients with knee OA, one of which was conducted in China.

Preclinical studies showed the potential for a greater than 98.5% reduction in the required dose for a disease like OA, which is currently being examined in Phase III clinical trials.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the X0002 description, mechanism of action, dosage and administration, research and development activities in osteoarthritis.
• Elaborated details on X0002 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the X0002 research and development activities in osteoarthritis across the United States, Europe, Canada and Korea.
• The report also covers the patents information with expiry timeline around X0002.
• The report contains forecasted sales of X0002 for osteoarthritis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for osteoarthritis.
• The report also features the SWOT analysis with analyst views for X0002 in osteoarthritis.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

X0002 Analytical Perspective by DelveInsight

• In-depth X0002 Market Assessment

This report provides a detailed market assessment of X0002 for osteoarthritis in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada and Korea. This segment of the report provides forecasted sales data from 2024 to 2032.

• X0002 Clinical Assessment

The report provides the clinical trials information of X0002 for osteoarthritis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for osteoarthritis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence X0002 dominance.
• Other emerging products for osteoarthritis are expected to give tough market competition to X0002 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of X0002 in osteoarthritis.
• Our in-depth analysis of the forecasted sales data of X0002 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the X0002 in osteoarthritis.

Key Questions

• What is the product type, route of administration and mechanism of action of X0002?
• What is the clinical trial status of the study related to X0002 in osteoarthritis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the X0002 development?
• What are the key designations that have been granted to X0002 for osteoarthritis?
• What is the forecasted market scenario of X0002 for osteoarthritis?
• What are the forecasted sales of X0002 in the six major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, along with Canada and Korea?
• What are the other emerging products available and how are these giving competition to X0002 for osteoarthritis?
• Which are the late-stage emerging therapies under development for the treatment of osteoarthritis?

Table of Contents

1. Report Introduction

2. X0002 Overview in Osteoarthritis

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. X0002 Market Assessment

• 5.1. Market Outlook of X0002 in Osteoarthritis
• 5.2. 6MM, Canada and Korea Analysis
  • 5.2.1. Market Size of X0002 in the 6MM, Canada and Korea for Osteoarthritis
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of X0002 in the United States for Osteoarthritis
  • 5.3.2. Market Size of X0002 in Germany for Osteoarthritis
  • 5.3.3. Market Size of X0002 in France for Osteoarthritis
  • 5.3.4. Market Size of X0002 in Italy for Osteoarthritis
  • 5.3.5. Market Size of X0002 in Spain for Osteoarthritis
  • 5.3.6. Market Size of X0002 in the United Kingdom for Osteoarthritis
  • 5.3.7. Market Size of X0002 in Canada for Osteoarthritis
  • 5.3.8. Market Size of X0002 in Korea for Osteoarthritis

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options